ClinicalTrials.gg
CompletedNCT04235686Updated Nov 16, 2026Results posted

8 Week Multi-site Study of MYDAYIS® for Bipolar Depression

A Phase 2 interventional study of Mydayis Extended-Release Capsule and Placebo in Bipolar Depression, sponsored by Mayo Clinic. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment

How we know

Updated Nov 16, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Bipolar Disorder by Mayo Clinic — 5 open to participants now, 6 under way, none of them phase 3. Bipolar Disorder · Mayo Clinic.

Enrollment
3rd of 12
77 · median 35
Started
2020
the only one that year
Phase 2
Only one
of the 13
Registered
8th of 13
by date

Among the 13 studies in Bipolar Disorder by Mayo Clinic, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2020, is the only one in phase 2, and was the 8th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

5 of the 13 studies in Bipolar Disorder by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Bipolar Disorder by Mayo Clinic, or all of them as a file.
02

Study summary

This protocol is a Phase 2 multi-site study which aims to evaluate the safety and effectiveness of MYDAYIS\® as adjunctive therapy for adults with bipolar depression. Results from this study WILL NOT be used to contribute to an approval of MYDAYIS \® for this indication.

03

Conditions studied

  • Bipolar Depression

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female between 18 and 65 years of age
  2. Bipolar I or II disorder as confirmed by structured diagnostic clinical interview for .
  3. Subsyndromal depressive symptoms or major depressive episode unresponsive to steady and stable (ie, at least 2 weeks) mood stabilization (eg, lithium, valproate, lamotrigine, carbamazepine/oxcarbamazepine, and/or atypical antipsychotic therapy) and non-psychotropic medication.
  4. Antidepressant therapy is allowed in the study as long as patients are also on a mood stabilizer. Patients will be enrolled provided that any needed modifications to the antidepressant would be made at least two weeks prior to randomization.
  5. Patients receiving psychotherapy will be allowed to be randomized provided therapy frequency does not change during the 8-week blinded phase.
  6. Symptom severity score on the Quick Inventory for Depressive Symptomatology - Clinician (QIDS-C16) ≥9, and the Clinical Global Impression for Bipolar Illness (CGI-BP) Depression Severity Scale ≥ 3.
  7. Patients on stimulants for comorbid attention deficit disorder (ADHD) and/or binge eating disorder (BED) will be enrolled provided that the stimulant can be tapered and discontinued at least one week prior to randomization; symptom severity inclusion criteria 4.1.3 or presence of subsyndromal symptoms must be met again prior to randomization.
  8. Patients with a prescribed opiate (eg. hydroxicodone) or other pain intervention for acute or chronic pain management will be allowed provided they: 1) use of a prescribed opiate or other pain intervention at a recommendation dose and established duration; 2) show no evidence of prescription misuse; 3) do not meet abuse or dependence criteria by SCID; 4) no known significant pharmacological interactions.
  9. Ability to travel for the assessment visits.

Exclusion criteria

Exclusion Criteria

  1. Inability to provide written .
  2. Inability to understand English.
  3. Score less than 86% correct (ie, one wrong) on comprehension assessment that reviews study goals.
  4. signs of acute suicidality from any of the following assessments:

    1. Response of > 2 on question #12 of QIDS-C or
    2. Response = 3 on the SCID Module A- #A19
  5. Medically serious suicide attempt within the past 6 months (medically serious defined as an ED evaluation and procedure and/or admit to inpatient unit such as internal medicine, cardiac, or ICU).
  6. Concomitant treatment with monoamine oxidase inhibitors (MAOIs); also, within 14 days following discontinuation of treatment with a monoamine oxidase inhibitor.
  7. Baseline Young Mania Rating Scale (YMRS) score ≥ 12.
  8. Patients with active psychosis (measured by a score >4 on YMRS question #8) or a diagnosis of schizophrenia, schizoaffective disorder, delusional, or schizophreniform disorder identified by structured clinical interview for .
  9. Active abuse or dependence of alcohol, opiates, or cannabis (nicotine dependence will be an exception) by structured clinical interview for DSM-IV-TR; patients meeting full remission for at least 3 months can be randomized.
  10. Positive toxicology screen for drugs of abuse (ie, cocaine, methamphetamine, illegal opiates).
  11. Positive toxicology screen for cannabis and a cannabis use disorder by structured clinical interview for DSM-IV-TR. Participants who use cannabis for recreational or medicinal purposes and fail the toxicology screen can potentially be included in the study only if they take the CUDIT-R and score a 12 or less
  12. Known lifetime history of cocaine or methamphetamine abuse or dependence identified by structured clinical interview for DSM-IV-TR.
  13. Active stimulant prescription abuse or dependence by structured clinical interview for DSM-IV-TR; patients meeting full remission for at least 6 months can be randomized.
  14. Known lifetime history of stimulant-induced mania.
  15. Known , such as angioedema or anaphylaxis, to amphetamines or other ingredients of MYDAYIS.
  16. Clinically unstable medical disease.
  17. Known history of a structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormality, coronary artery disease, stroke, or other serious cardiovascular problems.
  18. with clinically significant arrhythmias, conduction abnormalities, or voltage criteria met for left ventricular hypertrophy (unless cleared by cardiology consultation).
  19. Uncontrolled hypertension (>160/100) or tachycardia (heart rate >110).
  20. History of grand mal seizure; history of febrile seizure as infant permitted.
  21. Established vasculopathy or history of Raynaud's phenomena.
  22. Narrow angle glaucoma.
  23. Chronic kidney disease (CKD) > stage IIIa ( 40-59).
  24. Tourette syndrome.
  25. Women who are pregnant, lactating or of not using at least one adequate measure (ie, hormonal contraception-birth control pills, intrauterine devices (IUD), tubal ligation or condoms during sexual intercourse).
  26. Current positive test for SARS-CoV-2; those with previous COVID-19 illness and those who test positive for SARS-CoV-2 any time after starting study drug or placebo will be included.
  27. Otherwise excluded for administrative reasons and/or clinician judgment.
  28. Daily use of lorazepam (Ativan) at doses > 2 mg per day (or dose equivalent: clonazepam (Klonopin) > 1 mg, alprazolam (Xanax) > 1-2 mg, or diazepam (Valium) >20 mg) [58].
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
77 participants (actual)

Study arms

  • Active comparator
    Mydayis - Active

    MYDAYIS®, Oral administration, dose regimen for Double blind phase and open label phase. 12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days

    Drug: Mydayis Extended-Release Capsule

  • Placebo comparator
    Placebo

    Matching placebo, Oral administration, dose regimen for Double blind phase and open label phase. 12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days

    Drug: Placebo

Interventions

  • DrugMydayis Extended-Release Capsule

    Randomized, parallel - group, double-blind, placebo-controlled, flexible-dose adjunctive trial of MYDAYIS®

    Also known as: d-amphetamine / l-amphetamine

  • DrugPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score

    The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered tool used to measure the severity of depression and track changes during treatment. Total scores range from 0 to 60, with higher numbers indicating more severe depressive symptoms. The outcome measure was the mean percent reduction from baseline in participants' total MADRS score, with greater percent reductions indicating greater improvement in depressive symptoms.

    Time frame: Baseline to week 8

  2. Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score-Open Label Extension

    The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered tool used to measure the severity of depression and track changes during treatment. Total scores range from 0 to 60, with higher numbers indicating more severe depressive symptoms. The outcome measure was the mean absolute change from week 8 to week 16 in participants' total MADRS score. Negative values indicate a reduction in depressive symptom severity.

    Time frame: Week 8 to Week 16

Secondary outcomes

  1. Change in Quick Inventory for Depressive Symptomatology (QIDS-C-16 and QIDS-SR-16) Score

    The QIDS-C-16 (Quick Inventory of Depressive Symptomatology - Clinician) and QIDS-SR-16 (Quick Inventory of Depressive Symptomatology - Self Report) are 16-item questionnaires designed to assess the severity of depressive symptoms. They are widely used by healthcare providers to monitor treatment progress and symptom changes over time. They are scored the same. Scores are calculated by summing the responses to nine core symptom domains. The total score ranges from 0 to 27, with higher scores indicating greater depression severity. The outcome measure was mean percent reduction from baseline in total QIDS-C-16 and QIDS-SR-16 scores, with greater reductions indicating greater improvement in depressive symptoms.

    Time frame: Baseline to Week 8

  2. Remission

    The number of subjects who had treatment remission defined as having a Montgomery-Asberg Depression Rating Scale (MADRS) score \< 10. (Score Range 0-60)

    Time frame: Baseline to Week 8

  3. Change in General Anxiety Disorder 7-item (GAD-7) Scale Score

    The GAD-7 scale is used to assess anxiety symptoms in individuals. Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms.

    Time frame: Baseline to Week 8 visit 10

  4. Response

    The number of subjects who had a treatment response defined as a 50% reduction in Montgomery-Asberg Depression Rating Scale (MADRS) score (Range: 0-60).

    Time frame: Baseline to Week 8 visit 10

  5. Improvement of Clinical Global Impression for Bipolar Disorder (CGI-I) Score

    The number of subjects who had improvement in their CGI-I score. This scale evaluates how much the patient's illness has improved or worsened relative to their baseline state (prior to starting treatment). Scores range from 1-7 with lower scores indicating higher improvement.

    Time frame: Baseline to Week 8 visit 10

  6. Change in Young Mania Rating Scale (YMRS) Score

    The Young Mania Rating Scale (YMRS) is an 11-item clinician-administered questionnaire used to assess and measure the severity of manic symptoms. Scores range from 0 to 60, with higher scores indicating greater symptom severity. The outcome measure was mean percent change from baseline in the total YMRS score. A greater decrease from baseline (more negative percent change) indicates improvement in manic symptoms.

    Time frame: Baseline to Week 8

  7. Change in Young Mania Rating Scale (YMRS) Score-Open Label Extension

    The Young Mania Rating Scale (YMRS) is an 11-item clinician-administered questionnaire used to assess and measure the severity of manic symptoms. Scores range from 0 to 60, with higher scores indicating greater symptom severity. The outcome measure was mean change from week 8 to week 16 in the total YMRS score.

    Time frame: Week 8 to Week 16

  8. Change in Epworth Sleepiness Scale (ESS) Score

    The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire that measures the average level of daytime sleepiness. By rating the likelihood of dozing off in 8 daily scenarios, a total score ranging from 0 to 24 is calculated. A higher score indicates greater daytime sleepiness and increased severity of sleepiness symptoms. The outcome measure was the mean percent change from baseline in the total ESS score. A greater decrease from baseline (more negative percent change) indicates improvement in daytime sleepiness.

    Time frame: Baseline to Week 8

  9. Change in Fatigue Severity Scale (FSS) Score

    The Fatigue Severity Scale (FSS) evaluates how fatigue impacts daily life. It contains 9 statements, each rated on a 1-to-7 scale (1 = strongly disagree, 7 = strongly agree). Total scores range from 9 to 63 with higher scores indicating worse fatigue. The outcome measure was the mean percent change from baseline in the total FSS score. A greater decrease from baseline (more negative percent change) indicates improvement in fatigue severity.

    Time frame: Baseline to Week 8

  10. Change in Binge Eating Scale (BES) Score

    The Binge Eating Scale (BES) is a self-reported questionnaire designed to assess the presence and severity of binge eating behaviors and characteristics associated with binge eating. Total scores range from 0 to 48 with higher scores indicating greater severity of binge eating symptoms.

    Time frame: Baseline to Week 8

  11. Change in Rapid Eating and Activity Assessment for Patients (REAP) Score

    The Rapid Eating and Activity Assessment for Patients (REAP) is a self-reported questionnaire used to assess dietary habits and physical activity behaviors. Total REAP scores range from 0 to 27 with higher scores indicating healthier nutrition and physical activity behaviors. The outcome measure was the mean percent change from baseline in the total REAP score. A greater increase from baseline indicates improvement in dietary and physical activity behaviors.

    Time frame: Baseline to Week 8

  12. Change in Digit Symbol Substitution Test (DSST) Score

    The Digit Symbol Substitution Test (DSST) is a neuropsychological assessment of cognitive performance that measures processing speed, working memory, and visuomotor coordination. Participants are required to match symbols to corresponding number according to a provided key within a fixed time period of 90 seconds. The raw score is simply the total number of correctly matched symbols completed within the time limit (90 seconds). Scores range from 0 to the total number of correct responses achieved, with higher scores indicating better cognitive performance. The outcome measure was the mean percent change from baseline in DSST score. A greater increase from baseline indicates improvement in cognitive performance.

    Time frame: Baseline to Week 8

  13. Morningness-Eveningness Questionnaire (MEQ) Score

    The Morningness-Eveningness Questionnaire (MEQ) is a self-assessment tool used to determine a person's preferred timing for sleep and peak alertness during the day. Total scores range from 16 to 86 with higher scores indicating a stronger morning preference, whereas lower scores indicate a stronger evening preference.

    Time frame: Baseline

07

Results

Posted Nov 16, 2026

Participant flow

Participants were recruited based on clinician schedule review and social media campaigns at 2 academic medical centers between November 2020 and March 2025. The first participant was enrolled on November 17, 2020, and the last participant was enrolled on March 27, 2025.

Blind Phase (8 weeks)
Participant flow — Blind Phase (8 weeks)
MilestoneMydayis - ActivePlaceboMydayis-Active Open Label Extension
Started15170
Completed1390
Not completed280
Open Phase (8 weeks)
Participant flow — Open Phase (8 weeks)
MilestoneMydayis - ActivePlaceboMydayis-Active Open Label Extension
Started0024
Completed0024
Not completed000

Outcome measures

PrimaryChange in Montgomery-Asberg Depression Rating Scale (MADRS) Score

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered tool used to measure the severity of depression and track changes during treatment. Total scores range from 0 to 60, with higher numbers indicating more severe depressive symptoms. The outcome measure was the mean percent reduction from baseline in participants' total MADRS score, with greater percent reductions indicating greater improvement in depressive symptoms.

Time frame:
Baseline to week 8
Reported as:
Mean · percentage of reduction
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score
percentage of reductionMydayis - Active (Blinded Phase)Placebo (Blinded Phase)
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score62.3 (42.3 to 82.3)15.4 (-3.3 to 34.1)
PrimaryChange in Montgomery-Asberg Depression Rating Scale (MADRS) Score-Open Label Extension

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered tool used to measure the severity of depression and track changes during treatment. Total scores range from 0 to 60, with higher numbers indicating more severe depressive symptoms. The outcome measure was the mean absolute change from week 8 to week 16 in participants' total MADRS score. Negative values indicate a reduction in depressive symptom severity.

Time frame:
Week 8 to Week 16
Reported as:
Mean · score on a scale
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score-Open Label Extension
score on a scalePlacebo to Mydayis-Active (Open Label Extension)Mydayis-Active to Mydayis-Active (Open Label Extension)
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score-Open Label Extension-7.1 (-13.6 to -0.6)0.7 (-5.0 to 6.4)
SecondaryChange in Quick Inventory for Depressive Symptomatology (QIDS-C-16 and QIDS-SR-16) Score

The QIDS-C-16 (Quick Inventory of Depressive Symptomatology - Clinician) and QIDS-SR-16 (Quick Inventory of Depressive Symptomatology - Self Report) are 16-item questionnaires designed to assess the severity of depressive symptoms. They are widely used by healthcare providers to monitor treatment progress and symptom changes over time. They are scored the same. Scores are calculated by summing the responses to nine core symptom domains. The total score ranges from 0 to 27, with higher scores indicating greater depression severity. The outcome measure was mean percent reduction from baseline in total QIDS-C-16 and QIDS-SR-16 scores, with greater reductions indicating greater improvement in depressive symptoms.

Time frame:
Baseline to Week 8
Reported as:
Mean · percentage of reduction
Change in Quick Inventory for Depressive Symptomatology (QIDS-C-16 and QIDS-SR-16) Score
percentage of reductionMydayis - ActivePlacebo
QIDS-C55.5 (36.4 to 74.7)11.8 (-6.1 to 29.7)
QIDS-SR46.9 (27.5 to 66.4)13.5 (-4.0 to 31.1)
SecondaryRemission

The number of subjects who had treatment remission defined as having a Montgomery-Asberg Depression Rating Scale (MADRS) score \< 10. (Score Range 0-60)

Time frame:
Baseline to Week 8
Reported as:
Count of participants · Participants
Remission
ParticipantsMydayis - ActivePlacebo
Remission82
SecondaryChange in General Anxiety Disorder 7-item (GAD-7) Scale Score

The GAD-7 scale is used to assess anxiety symptoms in individuals. Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms.

Time frame:
Baseline to Week 8 visit 10
Reported as:
Mean · score on a scale
Change in General Anxiety Disorder 7-item (GAD-7) Scale Score
score on a scaleMydayis - ActivePlacebo
Change in General Anxiety Disorder 7-item (GAD-7) Scale Score8.7 (7.2 to 10.1)11.1 (9.7 to 12.5)
SecondaryResponse

The number of subjects who had a treatment response defined as a 50% reduction in Montgomery-Asberg Depression Rating Scale (MADRS) score (Range: 0-60).

Time frame:
Baseline to Week 8 visit 10
Reported as:
Count of participants · Participants
Response
ParticipantsMydayis - ActivePlacebo
Response102
SecondaryImprovement of Clinical Global Impression for Bipolar Disorder (CGI-I) Score

The number of subjects who had improvement in their CGI-I score. This scale evaluates how much the patient's illness has improved or worsened relative to their baseline state (prior to starting treatment). Scores range from 1-7 with lower scores indicating higher improvement.

Time frame:
Baseline to Week 8 visit 10
Reported as:
Count of participants · Participants
Improvement of Clinical Global Impression for Bipolar Disorder (CGI-I) Score
ParticipantsMydayis - ActivePlacebo
Improvement of Clinical Global Impression for Bipolar Disorder (CGI-I) Score92
SecondaryChange in Young Mania Rating Scale (YMRS) Score

The Young Mania Rating Scale (YMRS) is an 11-item clinician-administered questionnaire used to assess and measure the severity of manic symptoms. Scores range from 0 to 60, with higher scores indicating greater symptom severity. The outcome measure was mean percent change from baseline in the total YMRS score. A greater decrease from baseline (more negative percent change) indicates improvement in manic symptoms.

Time frame:
Baseline to Week 8
Reported as:
Mean · percentage of change
Change in Young Mania Rating Scale (YMRS) Score
percentage of changeMydayis - ActivePlacebo
Change in Young Mania Rating Scale (YMRS) Score2.9 (1.7 to 4.9)3.3 (2.1 to 5.4)
SecondaryChange in Young Mania Rating Scale (YMRS) Score-Open Label Extension

The Young Mania Rating Scale (YMRS) is an 11-item clinician-administered questionnaire used to assess and measure the severity of manic symptoms. Scores range from 0 to 60, with higher scores indicating greater symptom severity. The outcome measure was mean change from week 8 to week 16 in the total YMRS score.

Time frame:
Week 8 to Week 16
Reported as:
Mean · score on a scale
Change in Young Mania Rating Scale (YMRS) Score-Open Label Extension
score on a scalePlacebo to Mydayis-Active (Open Label Extension)Mydayis-Active to Mydayis-Active (Open Label Extension)
Change in Young Mania Rating Scale (YMRS) Score-Open Label Extension1.2 (0.5 to 2.9)5.0 (2.7 to 9.3)
SecondaryChange in Epworth Sleepiness Scale (ESS) Score

The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire that measures the average level of daytime sleepiness. By rating the likelihood of dozing off in 8 daily scenarios, a total score ranging from 0 to 24 is calculated. A higher score indicates greater daytime sleepiness and increased severity of sleepiness symptoms. The outcome measure was the mean percent change from baseline in the total ESS score. A greater decrease from baseline (more negative percent change) indicates improvement in daytime sleepiness.

Time frame:
Baseline to Week 8
Reported as:
Mean · percentage of change
Change in Epworth Sleepiness Scale (ESS) Score
percentage of changeMydayis - ActivePlacebo
Change in Epworth Sleepiness Scale (ESS) Score18.0 (-12.5 to 48.4)-23.5 (-55.2 to 8.1)
SecondaryChange in Fatigue Severity Scale (FSS) Score

The Fatigue Severity Scale (FSS) evaluates how fatigue impacts daily life. It contains 9 statements, each rated on a 1-to-7 scale (1 = strongly disagree, 7 = strongly agree). Total scores range from 9 to 63 with higher scores indicating worse fatigue. The outcome measure was the mean percent change from baseline in the total FSS score. A greater decrease from baseline (more negative percent change) indicates improvement in fatigue severity.

Time frame:
Baseline to Week 8
Reported as:
Mean · percentage of change
Change in Fatigue Severity Scale (FSS) Score
percentage of changeMydayis - ActivePlacebo
Change in Fatigue Severity Scale (FSS) Score25.9 (7.4 to 44.3)5.5 (-9.9 to 20.8)
SecondaryChange in Binge Eating Scale (BES) Score

The Binge Eating Scale (BES) is a self-reported questionnaire designed to assess the presence and severity of binge eating behaviors and characteristics associated with binge eating. Total scores range from 0 to 48 with higher scores indicating greater severity of binge eating symptoms.

Time frame:
Baseline to Week 8
Reported as:
Mean · score on a scale
Change in Binge Eating Scale (BES) Score
score on a scaleMydayis - ActivePlacebo
Change in Binge Eating Scale (BES) Score8.4 (5.3 to 11.4)12.0 (9.2 to 14.7)
SecondaryChange in Rapid Eating and Activity Assessment for Patients (REAP) Score

The Rapid Eating and Activity Assessment for Patients (REAP) is a self-reported questionnaire used to assess dietary habits and physical activity behaviors. Total REAP scores range from 0 to 27 with higher scores indicating healthier nutrition and physical activity behaviors. The outcome measure was the mean percent change from baseline in the total REAP score. A greater increase from baseline indicates improvement in dietary and physical activity behaviors.

Time frame:
Baseline to Week 8
Reported as:
Mean · percentage of change
Change in Rapid Eating and Activity Assessment for Patients (REAP) Score
percentage of changeMydayis - ActivePlacebo
Change in Rapid Eating and Activity Assessment for Patients (REAP) Score14.3 (7.3 to 21.2)-1.7 (-8.4 to 5.1)
SecondaryChange in Digit Symbol Substitution Test (DSST) Score

The Digit Symbol Substitution Test (DSST) is a neuropsychological assessment of cognitive performance that measures processing speed, working memory, and visuomotor coordination. Participants are required to match symbols to corresponding number according to a provided key within a fixed time period of 90 seconds. The raw score is simply the total number of correctly matched symbols completed within the time limit (90 seconds). Scores range from 0 to the total number of correct responses achieved, with higher scores indicating better cognitive performance. The outcome measure was the mean percent change from baseline in DSST score. A greater increase from baseline indicates improvement in cognitive performance.

Time frame:
Baseline to Week 8
Reported as:
Mean · percentage of change
Change in Digit Symbol Substitution Test (DSST) Score
percentage of changeMydayis - ActivePlacebo
Change in Digit Symbol Substitution Test (DSST) Score23.8 (9.1 to 38.5)10.5 (-3.2 to 24.3)
SecondaryMorningness-Eveningness Questionnaire (MEQ) Score

The Morningness-Eveningness Questionnaire (MEQ) is a self-assessment tool used to determine a person's preferred timing for sleep and peak alertness during the day. Total scores range from 16 to 86 with higher scores indicating a stronger morning preference, whereas lower scores indicate a stronger evening preference.

Time frame:
Baseline
Reported as:
Mean · score on a scale
Morningness-Eveningness Questionnaire (MEQ) Score
score on a scaleMydayis - ActivePlacebo
Morningness-Eveningness Questionnaire (MEQ) Score54.20 ± 11.5649.41 ± 9.32

Adverse events

Collected over Adverse events were collected up to 8 weeks in the blinded phase and up to an additional 8 weeks in the open label extension.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mydayis - Active0/15 (0%)0/15 (0%)15/15 (100%)
Placebo0/17 (0%)0/17 (0%)10/17 (58.8%)
Mydayis-Active Open Label Extension0/24 (0%)0/24 (0%)18/24 (75%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventMydayis - ActivePlaceboMydayis-Active Open Label Extension
HeadacheNervous system disorders5/154/178/24
IndigestionGastrointestinal disorders2/150/175/24
VomitingGastrointestinal disorders3/151/172/24
NauseaGastrointestinal disorders1/153/173/24
InsomniaPsychiatric disorders2/150/170/24
DiarrheaGastrointestinal disorders1/152/173/24
Aches/PainGeneral disorders1/150/172/24
FatigueGeneral disorders1/150/172/24
Dry MouthGastrointestinal disorders1/150/171/24
Tremor/TwitchingNervous system disorders1/150/170/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)Mydayis - ActivePlaceboTotal
Mean42.7 ± 13.034.2 ± 10.038.2 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Mydayis - ActivePlaceboTotal
Female101222
Male5510
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mydayis - ActivePlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White141428
More than one race022
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)Mydayis - ActivePlaceboTotal
United States151732
08

Study locations

2 sites
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
  • Lindner Center of Hope
    Mason, Ohio 45040, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jul 2025, 56 months.

Results were first posted in Nov 2026, 1 year 3 months after primary completion.

Of 42 non-industry phase 2 interventional studies under Bipolar Disorder, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 56 months is above that.

Counting every sponsor, half of 56 studies reached it within 33 months; a quarter within 20 and three quarters within 62.

Start moved once since we started tracking on Sep 25, 2026: Jul 2020 → Nov 2020, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2019
First posted
Jan 22, 2020
StartActual
Nov 17, 2020was Jul 2020
Primary completionActual
Jul 25, 2025
CompletionActual
Jul 25, 2025
Results first posted
Nov 16, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 16, 2026
Start date
Jul 17, 2020→Nov 17, 2020
Nov 16, 2026
Enrollment
74→77
Nov 16, 2026
Eligibility
Maximum age 55 Years→65 Years; 3 inclusion criteria edited, 6 added, 3 removed; 12 exclusion criteria edited, 12 added, 8 removed
What changed in the criteria
Inclusion criteria
  • EditedMale or female between 18 and 5565 years of age
  • EditedBipolar I or II disorder as confirmed by structured diagnostic clinical interview by Axis I of the SCID byfor DSM-IV-TR.
  • RemovedCurrently experiencing a major depressive episode unresponsive to stable (i.e. at least 4 weeks) anti-manic mood stabilizers (lithium, valproate) and/or antipsychotic therapy, with or without concomitant antidepressant therapy.
  • AddedSubsyndromal depressive symptoms or major depressive episode unresponsive to steady and stable (ie, at least 2 weeks) mood stabilization (eg, lithium, valproate, lamotrigine, carbamazepine/oxcarbamazepine, and/or atypical antipsychotic therapy) and non-psychotropic medication.
  • AddedAntidepressant therapy is allowed in the study as long as patients are also on a mood stabilizer. Patients will be enrolled provided that any needed modifications to the antidepressant would be made at least two weeks prior to randomization.
  • AddedPatients receiving psychotherapy will be allowed to be randomized provided therapy frequency does not change during the 8-week blinded phase.
  • EditedSymptom severity score ≥11 on the self-report version of the Quick Inventory for Depressive Symptomatology (QIDS-SR16) or score ≥11 on the Quick Inventory for Depressive Symptomatology - Clinician (QIDS-C16) ≥9, and ≥ 3 on the Clinical Global Impression for Bipolar Illness (CGI-BP) Depression Severity Scale ≥ 3.
  • RemovedPatients with a comorbid attention deficit disorder and binge eating disorder will be included.
  • RemovedPatients will be allowed to continue with their behavioral treatments (ie. CBT) targeted at their primary diagnosis.
  • AddedPatients on stimulants for comorbid attention deficit disorder (ADHD) and/or binge eating disorder (BED) will be enrolled provided that the stimulant can be tapered and discontinued at least one week prior to randomization; symptom severity inclusion criteria 4.1.3 or presence of subsyndromal symptoms must be met again prior to randomization.
  • AddedPatients with a prescribed opiate (eg. hydroxicodone) or other pain intervention for acute or chronic pain management will be allowed provided they: 1) use of a prescribed opiate or other pain intervention at a recommendation dose and established duration; 2) show no evidence of prescription misuse; 3) do not meet abuse or dependence criteria by SCID; 4) no known significant pharmacological interactions.
  • AddedAbility to travel for the assessment visits.
Exclusion criteria
  • RemovedAbility to provide informed consent and understand fully English and score ≥ 90% on comprehension test questionnaire that reviews study goals.
  • AddedInability to provide written informed consent.
  • AddedInability to understand English.
  • AddedScore less than 86% correct (ie, one wrong) on comprehension assessment that reviews study goals.
  • EditedClinically significant signs of acute suicidality from any of the following assessments:
  • RemovedResponse ≥ 4 on MADRS question # 10
  • EditedResponse ≥of > 2 on question #12 of QIDS-C or QIDS-SR question # 12
  • RemovedYes response on Columbia Suicide Severity Scale (CSSR) Question # 3 (ideation without plan or intent) ,Question #4 (ideation with intent, but no plan), or Question # 5 (ideation, intent, and plan)
  • RemovedSuicide attempt within the past year, as defined by the Columbia-Suicide Severity Scale
  • RemovedKnown lifetime history of DSM-IV-TR diagnosis of cocaine or methamphetamine abuse or dependence. Nicotine dependence will be an exception.
  • AddedResponse = 3 on the SCID Module A- #A19
  • AddedMedically serious suicide attempt within the past 6 months (medically serious defined as an ED evaluation and procedure and/or admit to inpatient unit such as internal medicine, cardiac, or ICU).
  • EditedConcomitant treatment with monoamine oxidase inhibitors (MAOIs), and; also, within 14 days following discontinuation of treatment with a monoamine oxidase inhibitor.
  • EditedBaseline Young Mania Rating Scale (YMRS) score ≥ 812.
  • EditedPatients with active psychosis identified(measured by SCIDa score >4 on YMRS question #8) or a diagnosis of schizophrenia, schizoaffective disorder, delusional, or schizophreniform disorder identified by structured clinical interview for DSM-IV-TR.
  • AddedActive abuse or dependence of alcohol, opiates, or cannabis (nicotine dependence will be an exception) by structured clinical interview for DSM-IV-TR; patients meeting full remission for at least 3 months can be randomized.
  • EditedPositive toxicology screen for drugs of abuse (ie., cocaine, methamphetamine, cannabis,illegal opiates).
  • RemovedKnown history of prescription abuse of stimulants.
  • AddedPositive toxicology screen for cannabis and a cannabis use disorder by structured clinical interview for DSM-IV-TR. Participants who use cannabis for recreational or medicinal purposes and fail the toxicology screen can potentially be included in the study only if they take the CUDIT-R and score a 12 or less
  • AddedKnown lifetime history of cocaine or methamphetamine abuse or dependence identified by structured clinical interview for DSM-IV-TR.
  • AddedActive stimulant prescription abuse or dependence by structured clinical interview for DSM-IV-TR; patients meeting full remission for at least 6 months can be randomized.
  • EditedLifetimeKnown lifetime history of stimulant-induced mania.
  • RemovedActive abuse or dependence of alcohol, opiates or cannabis that is either current or less than 3 months full remission.
  • EditedKnown history of a structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormality, coronary artery disease, stroke, or other serious cardiovascular problems.
  • EditedECG with clinically significant arrhythmias, conduction abnormalities, or voltage criteria met for left ventricular hypertrophy (unless cleared by cardiology consultation).
  • ChangedBefore Patients with end stage renal disease (ESRD).Now Chronic kidney disease (CKD) > stage IIIa (GFR 40-59).
  • EditedTourette's syndrome.
  • EditedWomen who are pregnant, lactating or of child-bearing potential and not using at least one adequate contraceptive measure (i.e.ie, hormonal contraception-birth control pills-, intrauterine devices (IUD), tubal ligation or condoms during sexual intercourse).

…and 4 more changes, on the record history on ClinicalTrials.gov ↗

Nov 16, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedChange in Montgomery-Asberg Depression Rating Scale (MADRS) scoreScoreTime frame: Baseline to week 8 visit 10 → Baseline to week 8
  • AddedChange in Montgomery-Asberg Depression Rating Scale (MADRS) Score-Open Label ExtensionTime frame: Week 8 to Week 16
Nov 16, 2026
Documents
Secondary outcomes
10 edited, 1 time frame changed, 1 added, 2 description edited
What changed in the outcomes
  • EditedChange in Quick Inventory for Depressive Symptomatology (QIDS-C-16 and QIDS-SR-16) scoreScoreTime frame: Baseline to Week 8 visit 10 → Baseline to Week 8
  • EditedChange in General Anxiety Disorder 7-item scale score(GAD-7) Scale ScoreTime frame: Baseline to Week 8 visit 10
  • EditedChange inImprovement of Clinical Global Impression for Bipolar Disorder (CGI-BPI) scoreScoreTime frame: Baseline to Week 8 visit 10
  • EditedChange in Young Mania Rating Scale (YMRS) scoreScoreTime frame: Baseline to Week 8 visit 10 → Baseline to Week 8
  • EditedChange in Epworth SleepinessYoung Mania Rating Scale (ESSYMRS) scoreScore-Open Label ExtensionTime frame: Baseline to Week 8 visit 10 → Week 8 to Week 16
  • EditedChange in Fatigue SeverityEpworth Sleepiness Scale (FSSESS) scoreScoreTime frame: Baseline to Week 8 visit 10 → Baseline to Week 8
  • EditedChange in Binge EatingFatigue Severity Scale (BESFSS) scoreScoreTime frame: Baseline to Week 8 visit 10 → Baseline to Week 8
  • EditedChange in Morningness-Eveningness QuestionnaireBinge Eating Scale (MEQBES) scoreScoreTime frame: Baseline to Week 8 visit 10 → Baseline to Week 8
  • EditedChange in Rapid Eating and Activity Assessment for Patients (REAP) scoreScoreTime frame: Baseline to Week 8 visit 10 → Baseline to Week 8
  • EditedChange in Digit Symbol Substitution Test (DSST) scoreScoreTime frame: Baseline to Week 8 visit 10 → Baseline to Week 8
  • AddedMorningness-Eveningness Questionnaire (MEQ) ScoreTime frame: Baseline
  • Time frameRemissionBaseline to Week 8 visit 10 → Baseline to Week 8
  • DescriptionRemission: how it is measured was reworded
  • DescriptionResponse: how it is measured was reworded
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Results posted
    Start date Jul 17, 2020→Nov 17, 2020
    Enrollment 74→77
    Eligibility Maximum age 55 Years→65 Years; 3 inclusion criteria edited, 6 added, 3 removed; 12 exclusion criteria edited, 12 added, 8 removed
    What changed in the criteria
    Inclusion criteria
    • EditedMale or female between 18 and 5565 years of age
    • EditedBipolar I or II disorder as confirmed by structured diagnostic clinical interview by Axis I of the SCID byfor DSM-IV-TR.
    • RemovedCurrently experiencing a major depressive episode unresponsive to stable (i.e. at least 4 weeks) anti-manic mood stabilizers (lithium, valproate) and/or antipsychotic therapy, with or without concomitant antidepressant therapy.
    • AddedSubsyndromal depressive symptoms or major depressive episode unresponsive to steady and stable (ie, at least 2 weeks) mood stabilization (eg, lithium, valproate, lamotrigine, carbamazepine/oxcarbamazepine, and/or atypical antipsychotic therapy) and non-psychotropic medication.
    • AddedAntidepressant therapy is allowed in the study as long as patients are also on a mood stabilizer. Patients will be enrolled provided that any needed modifications to the antidepressant would be made at least two weeks prior to randomization.
    • AddedPatients receiving psychotherapy will be allowed to be randomized provided therapy frequency does not change during the 8-week blinded phase.
    • EditedSymptom severity score ≥11 on the self-report version of the Quick Inventory for Depressive Symptomatology (QIDS-SR16) or score ≥11 on the Quick Inventory for Depressive Symptomatology - Clinician (QIDS-C16) ≥9, and ≥ 3 on the Clinical Global Impression for Bipolar Illness (CGI-BP) Depression Severity Scale ≥ 3.
    • RemovedPatients with a comorbid attention deficit disorder and binge eating disorder will be included.
    • RemovedPatients will be allowed to continue with their behavioral treatments (ie. CBT) targeted at their primary diagnosis.
    • AddedPatients on stimulants for comorbid attention deficit disorder (ADHD) and/or binge eating disorder (BED) will be enrolled provided that the stimulant can be tapered and discontinued at least one week prior to randomization; symptom severity inclusion criteria 4.1.3 or presence of subsyndromal symptoms must be met again prior to randomization.
    • AddedPatients with a prescribed opiate (eg. hydroxicodone) or other pain intervention for acute or chronic pain management will be allowed provided they: 1) use of a prescribed opiate or other pain intervention at a recommendation dose and established duration; 2) show no evidence of prescription misuse; 3) do not meet abuse or dependence criteria by SCID; 4) no known significant pharmacological interactions.
    • AddedAbility to travel for the assessment visits.
    Exclusion criteria
    • RemovedAbility to provide informed consent and understand fully English and score ≥ 90% on comprehension test questionnaire that reviews study goals.
    • AddedInability to provide written informed consent.
    • AddedInability to understand English.
    • AddedScore less than 86% correct (ie, one wrong) on comprehension assessment that reviews study goals.
    • EditedClinically significant signs of acute suicidality from any of the following assessments:
    • RemovedResponse ≥ 4 on MADRS question # 10
    • EditedResponse ≥of > 2 on question #12 of QIDS-C or QIDS-SR question # 12
    • RemovedYes response on Columbia Suicide Severity Scale (CSSR) Question # 3 (ideation without plan or intent) ,Question #4 (ideation with intent, but no plan), or Question # 5 (ideation, intent, and plan)
    • RemovedSuicide attempt within the past year, as defined by the Columbia-Suicide Severity Scale
    • RemovedKnown lifetime history of DSM-IV-TR diagnosis of cocaine or methamphetamine abuse or dependence. Nicotine dependence will be an exception.
    • AddedResponse = 3 on the SCID Module A- #A19
    • AddedMedically serious suicide attempt within the past 6 months (medically serious defined as an ED evaluation and procedure and/or admit to inpatient unit such as internal medicine, cardiac, or ICU).
    • EditedConcomitant treatment with monoamine oxidase inhibitors (MAOIs), and; also, within 14 days following discontinuation of treatment with a monoamine oxidase inhibitor.
    • EditedBaseline Young Mania Rating Scale (YMRS) score ≥ 812.
    • EditedPatients with active psychosis identified(measured by SCIDa score >4 on YMRS question #8) or a diagnosis of schizophrenia, schizoaffective disorder, delusional, or schizophreniform disorder identified by structured clinical interview for DSM-IV-TR.
    • AddedActive abuse or dependence of alcohol, opiates, or cannabis (nicotine dependence will be an exception) by structured clinical interview for DSM-IV-TR; patients meeting full remission for at least 3 months can be randomized.
    • EditedPositive toxicology screen for drugs of abuse (ie., cocaine, methamphetamine, cannabis,illegal opiates).
    • RemovedKnown history of prescription abuse of stimulants.
    • AddedPositive toxicology screen for cannabis and a cannabis use disorder by structured clinical interview for DSM-IV-TR. Participants who use cannabis for recreational or medicinal purposes and fail the toxicology screen can potentially be included in the study only if they take the CUDIT-R and score a 12 or less
    • AddedKnown lifetime history of cocaine or methamphetamine abuse or dependence identified by structured clinical interview for DSM-IV-TR.
    • AddedActive stimulant prescription abuse or dependence by structured clinical interview for DSM-IV-TR; patients meeting full remission for at least 6 months can be randomized.
    • EditedLifetimeKnown lifetime history of stimulant-induced mania.
    • RemovedActive abuse or dependence of alcohol, opiates or cannabis that is either current or less than 3 months full remission.
    • EditedKnown history of a structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormality, coronary artery disease, stroke, or other serious cardiovascular problems.
    • EditedECG with clinically significant arrhythmias, conduction abnormalities, or voltage criteria met for left ventricular hypertrophy (unless cleared by cardiology consultation).
    • ChangedBefore Patients with end stage renal disease (ESRD).Now Chronic kidney disease (CKD) > stage IIIa (GFR 40-59).
    • EditedTourette's syndrome.
    • EditedWomen who are pregnant, lactating or of child-bearing potential and not using at least one adequate contraceptive measure (i.e.ie, hormonal contraception-birth control pills-, intrauterine devices (IUD), tubal ligation or condoms during sexual intercourse).

    …and 4 more changes, on the record history on ClinicalTrials.gov ↗

    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedChange in Montgomery-Asberg Depression Rating Scale (MADRS) scoreScoreTime frame: Baseline to week 8 visit 10 → Baseline to week 8
    • AddedChange in Montgomery-Asberg Depression Rating Scale (MADRS) Score-Open Label ExtensionTime frame: Week 8 to Week 16
    Secondary outcomes 10 edited, 1 time frame changed, 1 added, 2 description edited
    What changed in the outcomes
    • EditedChange in Quick Inventory for Depressive Symptomatology (QIDS-C-16 and QIDS-SR-16) scoreScoreTime frame: Baseline to Week 8 visit 10 → Baseline to Week 8
    • EditedChange in General Anxiety Disorder 7-item scale score(GAD-7) Scale ScoreTime frame: Baseline to Week 8 visit 10
    • EditedChange inImprovement of Clinical Global Impression for Bipolar Disorder (CGI-BPI) scoreScoreTime frame: Baseline to Week 8 visit 10
    • EditedChange in Young Mania Rating Scale (YMRS) scoreScoreTime frame: Baseline to Week 8 visit 10 → Baseline to Week 8
    • EditedChange in Epworth SleepinessYoung Mania Rating Scale (ESSYMRS) scoreScore-Open Label ExtensionTime frame: Baseline to Week 8 visit 10 → Week 8 to Week 16
    • EditedChange in Fatigue SeverityEpworth Sleepiness Scale (FSSESS) scoreScoreTime frame: Baseline to Week 8 visit 10 → Baseline to Week 8
    • EditedChange in Binge EatingFatigue Severity Scale (BESFSS) scoreScoreTime frame: Baseline to Week 8 visit 10 → Baseline to Week 8
    • EditedChange in Morningness-Eveningness QuestionnaireBinge Eating Scale (MEQBES) scoreScoreTime frame: Baseline to Week 8 visit 10 → Baseline to Week 8
    • EditedChange in Rapid Eating and Activity Assessment for Patients (REAP) scoreScoreTime frame: Baseline to Week 8 visit 10 → Baseline to Week 8
    • EditedChange in Digit Symbol Substitution Test (DSST) scoreScoreTime frame: Baseline to Week 8 visit 10 → Baseline to Week 8
    • AddedMorningness-Eveningness Questionnaire (MEQ) ScoreTime frame: Baseline
    • Time frameRemissionBaseline to Week 8 visit 10 → Baseline to Week 8
    • DescriptionRemission: how it is measured was reworded
    • DescriptionResponse: how it is measured was reworded
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04235686
Lead sponsor
Mayo Clinic
Collaborators
Lindner Center of HOPE
Responsible party
Mark Frye (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Jan 22, 2020
Start date
Nov 17, 2020
Primary completion
Jul 25, 2025
Completion
Jul 25, 2025
Results posted
Nov 16, 2026
Last update
Nov 16, 2026

Study contacts

Mark A Frye
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion